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ABSTRACT
Introduction: Six genotypes of the hepatitis C virus (HCV) have been identiﬁ ed thus far, and their distribution is well deﬁ ned. 
Genotype 1, which is the most prevalent worldwide, is always compared to genotypes 2 and 3, particularly in terms of treatment 
response. However, little is known about the differences between genotypes 2 and 3 because these genotypes are analyzed 
together in most studies. Therefore, the aim of this study was to evaluate differences in the clinical, epidemiological, laboratory, 
and histological parameters between HCV-2 and HCV-3. Methods: Patients with chronic hepatitis C infected with genotypes 2 
and 3 were studied retrospectively and compared according to clinical, laboratory, and histological aspects. Hepatitis C virus-
ribonucleic acid (HCV-RNA) was analyzed quantitatively by TaqMan® real-time PCR, and the HCV genotype was determined 
by sequencing the 5’-untranslated region. Results: A total of 306 patients with chronic HCV-2 (n=50) and HCV-3 (n = 256) 
were studied. Subtype 2b (n=17/50) and subtype 3a (n=244/256) were the most prevalent among patients infected with HCV-2 
and HCV-3, respectively. The mean age was 47 ± 10 years, and there was a predominance of men in the group studied (61%). 
Comparative analysis between HCV-2 and HCV-3 showed a younger age (p=0.002), less prevalence of arterial hypertension 
(p=0.03), higher serum albumin levels (p=0.01), more advanced stage of liver ﬁ brosis (p=0.03), and higher frequency of steatosis 
in patients with HCV-3 (p=0.001). After multivariate regression analysis, all the variables, except serum albumin, remained as 
variables associated with HCV-3 in the ﬁ nal model. Conclusions: Clinical and histological differences exist between HCV-2 and 
HVC-3, which suggests the need for separate analyses of these genotypes. 
Keywords: Hepatitis C. HCV-2. HCV-3. Fibrosis.
Hepatitis C affects thousands of people around the world, 
causes chronic liver disease that can progress to liver cirrhosis, 
and is a leading cause of liver transplantation. The hepatitis 
C virus (HCV) is characterized by genetic heterogeneity, 
which permits its classiﬁ cation into distinct genotypes and 
subtypes by phylogenetic analysis1. This genetic diversity is 
related to the origin of the virus, its interesting evolution, its 
geographic and epidemiological pattern of dissemination, and 
its long persistence in humans2,3. Simmonds et al.1 proposed 
the classiﬁ cation of HCV into six viral genotypes with several 
subtypes: 1 (1a, 1b, 1c), 2 (2a, 2b, 2c), 3 (3a, 3b), 4, 5 (5a), 
and 6. Genotypes 1a and 1b are the most prevalent in western 
countries1, with genotype 1b being the most common in 
Europe4-6 and genotype 1a being the most common in the United 
States7,8. Genotype 2 and its subtypes predominate in western 
Africa9-11. Genotype 3a is the second most common genotype in 
Europe after genotype 14,6. Genotype 4 is prevalent in the Middle 
East12-14 and in Central Africa15-17, while genotype 5 is common 
in South Africa1,18, and genotype 6 is found mainly in South 
Asia19-21. Genotype 7 has been found in Vietnamese patients with 
chronic hepatitis C, although some authors have advocated that 
it should be reclassiﬁ ed as a subtype of genotype 622.
In addition to the wide geographic distribution of HCV 
genotypes and subtypes, HCV exhibits a specific pattern 
of transmission. For example, genotypes 1a, 3a, and 4 are 
associated mainly with intravenous drug use, while genotypes 
1b and 2 are associated with transmission through blood 
transfusion23-25. With respect to the treatment of chronic hepatitis 
C, genotype 1 is less responsive to antiviral therapy based on 
pegylated interferon and ribavirin26. In contrast, genotypes 2 and 
3 show higher response rates to antiviral treatment, and their 
treatment duration is shorter compared to that of genotype 127.
In most studies, patients infected with genotype 1 are 
compared to those infected with genotypes 2 and 3, particularly 
in terms of treatment response. Moreover, little is known about 
the differences between genotypes 2 and 3 because these 
genotypes are usually analyzed together. The aim of the present 
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study was to evaluate the distribution of HCV genotypes 2 
and 3 and their subtypes as well as to determine differences 
or similarities in clinical, laboratory, and histopathological 
parameters between these two genotypes.
Patients with chronic hepatitis C caused by genotypes 
2 and 3 who were evaluated between 1994 and 2011 at the 
Hepatitis Unit of the Department of Gastroenterology, Federal 
University of São Paulo, were studied retrospectively. The 
criteria for inclusion in the study were as follows: age of 
18 years or older, detection of HCV-RNA, and identiﬁ cation of 
HCV-2 and HCV-3. Patients who were co-infected with human 
immunodeﬁ ciency virus (HIV) or hepatitis B virus (HBV), 
organ transplant recipients, patients with end-stage renal disease, 
and patients with alcohol abuse were excluded from the study. 
Clinical, laboratory, and histological variables were compared 
between patients with HCV-2 and HCV-3. 
Clinical and laboratory assessment
The following clinical variables were analyzed: gender, 
age, parenteral transmission risk factors (transfusion of 
blood and blood derivatives and/or intravenous drug use), 
estimated duration of infection in patients with a known 
parenteral transmission risk factor, body mass index (BMI), 
diabetes mellitus, and arterial hypertension. Laboratory 
tests included the measurement of serum levels of aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
gamma-glutamyltransferase (GGT), alkaline phosphatase (AP), 
bilirubin, albumin, cholesterol, triglycerides, glucose, platelet 
count, and prothrombin activity (PA). 
Molecular tests
Qualitative HCV-RNA was detected by PCR using the 
Amplicor Hepatitis C Virus Test, version 2.0 (Roche Molecular 
Systems, Branchburg, NJ, USA) with a detection limit of 50IU/
mL. HCV genotyping was performed by ampliﬁ cation followed 
by hybridization of the HCV 5’-untranslated region (INNo-LiPA 
HCV II, Innogenetics NV, Belgium)
Histological analysis
Histological analysis was used to evaluate the activity grade 
and ﬁ brosis stage according to the METAVIR system. If no liver 
biopsy was available, the patients were classiﬁ ed as cirrhotic in 
the case of a suggestive radiological image (reduction in liver 
size, heterogeneous liver, and increased portal vein caliber) 
and/or evidence of portal hypertension based on the presence 
of esophageal varices upon digestive endoscopy. The presence 
of steatosis with or without steatohepatitis was analyzed, and 
steatohepatitis was classiﬁ ed according to the nonalcoholic fatty 
liver disease activity score28.
Statistical analysis
Numerical variables are reported as means and standard 
deviations, and categorical variables are expressed as absolute 
and relative frequencies. Analyses of skewness and kurtosis and 
the Kolmogorov-Smirnov test were used to determine whether 
continuous variables showed a normal distribution. Categorical 
variables were compared using the chi-square test and Fisher’s 
exact test, when necessary. Student’s t-test and the Mann-
Whitney test were applied to compare numerical variables. 
Logistic regression analysis was performed to identify variables 
that were independently associated with HCV-3. For all tests, 
p<0.05 was considered statistically significant. Statistical 
analysis was performed using Statistical Package for the Social 
Sciences (SPSS) 20.0 software (SPSS, Chicago, IL, USA).
Ethical considerations
This study was approved by the Ethics Committee of the 
Federal University of São Paulo.
A total of 306 patients with HCV-2 (n=50) and HCV-3 
(n=256) were studied, and HCV-3 was more (84%) common. 
Subtype 2b (34%) was the most prevalent among patients 
infected with HCV-2 (n=50). Subtype 3a was identiﬁ ed in 
244 (95%) of the 256 patients infected with HCV-3.
There was a predominance of men in the group of 306 (61%) 
patients, and the mean age was 47 ± 10 years. Risk factors for 
parenteral transmission were identiﬁ ed in 54% of the patients, 
with a transfusion risk identiﬁ ed in 37% of the patients and 
an intravenous drug use risk identiﬁ ed in 17% of the patients. 
The mean estimated duration of infection was 23±8 years. 
Arterial hypertension and diabetes mellitus were observed in 
19% and 11% of cases, respectively. A BMI ≥ 25kg/m2 was a 
characteristic of 56% of the patients; of these patients, 35% 
were overweight and 21% were obese. Elevated cholesterol 
and triglyceride levels were observed in 5% and 8% of cases, 
respectively. These data and the mean ALT, AST, GGT, and AP 
levels are shown in Table 1.
With respect to histology, an activity grade ≥2 was observed 
in 62% of the patients, and a ﬁ brosis stage >2 was observed in 
32% of the patients. Hepatic steatosis was present in 72% of 
the patients, whereas steatohepatitis was observed in only 3.5%.
A comparative analysis between HCV-2 and HCV-3 
showed a younger age (p=0.002), less prevalence of arterial 
hypertension (p=0.03), higher serum albumin levels (p=0.01), 
more advanced stage of liver ﬁ brosis (p=0.03), and higher 
frequency of steatosis in patients with HCV-3 (p=0.001). In 
addition, patients infected with HCV-3 tended to present a higher 
frequency of risk factors for parenteral transmission (p=0.06) 
and higher aminotransferase levels (Table 2). A comparison of 
serum cholesterol and triglyceride levels between genotypes 
was not possible because these parameters were only altered 
in a small number of patients.
Age, arterial hypertension, serum albumin levels, liver 
fibrosis, and steatosis were the variables included in the 
multivariate logistic regression analysis. The results of the 
analysis indicated that all the variables, except the serum albumin 
levels, remained independently associated with HCV-3 (Table 3).
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TABLE 1 - Clinical, laboratory, and histological characteristics of 
patients with chronic hepatitis C caused by genotypes 2 and 3.
 Total
Characteristics (n = 306)
Age (years)* 48 ± 10
Gender (%) 
male  61.0
female 39.0
Parenteral transmission risk n (%) 
blood transfusion 106    36.0
intravenous drug use 51     18.0
Duration of infection (years)* 23 ± 8.3
Diabetes mellitus 11.0
Arterial hypertension 19.0
BMI ≥25kg/m2 56.0
AST (xULN)* 1.9 ± 1.5
ALT (xULN)* 2.5 ± 1.9
Alkaline phosphatase (xULN)* 0.6 ± 0.7
GGT (xULN)* 2.1 ± 2.1
Bilirubin (mg/dL)* 0.93 ± 0.84
Prothrombin activity (%)* 90.6 ± 13
Albumin (g/dL)* 4.2 ± 0.5
Platelets (n/mm3)* 183,843 ± 66,575
Cholesterol ≥ 200/dL 5.0
Triglycerides ≥ 150mg/dL 8.0
Fibrosis (%) 
0-2 68.0
3-4 32.0
cirrhosis 21.0
Activity grade (%) 
0-1 38.0
2-3 62.0
Hepatic steatosis (%)  72.0
Genotype (%) 
2/2a/2b/2c/2a,c 3.0/4.0/6.0/1.0/2.0
3a 84.0
BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine 
aminotransferase; GGT: gamma-glutamyltransferase; ULN: upper limit 
of normal. *Values are expressed as the mean ± standard deviation. 
Histological analysis was performed according to the METAVIR system.
The distribution of HCV genotypes 2 and 3 and their subtypes 
varies according to geographic region. In the present study, which 
evaluated different aspects of HVC-2 and HVC-3, genotype 3 
was more prevalent (84% of cases), whereas genotype 2 was 
identiﬁ ed in only 16% of cases. Genotypes 3a, 2a, and 2b were 
the most common subtypes.
Studies conducted in Brazil have shown a predominance 
of genotype 3 over genotype 2 among non-genotype-1 patients 
in all regions of the country. Campiotto et al.29 studied the 
distribution of HCV genotypes and serotypes in different 
regions of Brazil and found genotype 3 in 30% of cases, whereas 
genotype 2 was identiﬁ ed in only 4.6% of the subjects. 
An investigation of the demographic and epidemiological 
differences between patients infected with HVC-2 and HVC-3 
showed that patients with HCV-2 had a higher mean age. In 
addition, parenteral transmission of the virus tended to be more 
frequent among subjects with HCV-3. From an epidemiological 
point of view, these ﬁ ndings appear to be related because genotype 
3 is strongly associated with intravenous drug use, which is more 
frequent among young individuals. Katsoulidou et al.30 studied 
1,686 patients with chronic HCV in Greece and mainly identiﬁ ed 
genotype 3 among patients who contracted the infection through 
the use of intravenous drugs (58%). Taken together, these results 
suggest that genotype 3 was recently introduced in the population3. 
In fact, HCV genotype incidence data have shown a 1.5-fold 
reduction in the prevalence of genotype 2 between 1970 and 1990 
and a 13-fold increase in that of genotype 3 over the same period30.
The evaluation of clinical and laboratory differences 
between HVC-2 and HVC-3 showed that arterial hypertension 
was more frequent among patients with HCV-2. This ﬁ nding 
might be due to the older age of these patients, as arterial 
hypertension is more frequent among older subjects. The 
laboratory parameters, with the exception of albumin, were 
similar for the two genotypes. Although the albumin levels were 
approximately normal in patients with HCV-3, they were slightly 
higher compared to those in patients with HCV-2. Despite this 
mathematical difference, this ﬁ nding appears to be irrelevant 
from a clinical point of view. 
Hepatic steatosis and advanced ﬁ brosis were more frequent 
among patients infected with HCV-3 compared to patients 
with HCV-2. Studies have demonstrated a higher prevalence 
of steatosis in patients infected with genotype 3 compared to 
patients infected with other genotypes31. Rubbia-Brandt et al.32 
studied 101 patients with chronic hepatitis C, excluding patients 
with risk factors for nonalcoholic fatty liver disease, and they 
observed hepatic steatosis in 41% of the patients, irrespective 
of gender, age, or source of infection. Genotype 3 was more 
frequent than the other genotypes. The physiopathological 
mechanisms underlying the higher frequency of hepatic steatosis 
in patients with hepatitis C and genotype 3 suggest that the virus 
may have a cytopathic effect. According to Barba et al. 33, hepatic 
steatosis in hepatitis C appears to be the result of interference 
with the expression of genes involved in lipid metabolism.
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TABLE 3 - Final model illustrating multivariate logistic regression analysis of variables associated with HCV-3.
            95%CI
Characteristics p value OR lower upper
Age (younger)  0.007 0.94 0.905 0.984
Arterial hypertension (less frequent) 0.03 0.37 0.145 0.943
Albumin (g/dL) 0.05 2.41 0.995 5.879
Fibrosis 3-4 0.03 3.02 1.058 8.624
Hepatic steatosis  0.005 3.38 1.457 7.845
HCV: hepatitis C virus; OR: odds ratio; 95%CI: 95% conﬁ dence interval.
TABLE 2 - Comparative analysis of clinical, laboratory, and histological variables in 306 patients with chronic hepatitis C genotypes 2 and 3.
 Genotype 2 Genotype 3 
Characteristics (n = 50) (n = 256) p value
Age (years)a  52 ± 9 47 ± 10 0.002
Male* 56 62 0.4
Parenteral transmission risk* 42 56 0.06
Duration of infection (years)a 21 ± 9 24 ± 7 0.2
Diabetes* 8 11 0.5
Arterial hypertension* 30 17 0.03
BMI ≥ 25kg/m2, yes/no* 17/18 83/82 0.7
AST (xULN)a  1.6 ± 1.4 2.0 ± 1.5 0.07
ALT (xULN)a  2.0 ± 1.8 2.6 ± 2.1 0.06
Alkaline phosphatase (xULN)a 0.8 ± 1.7 0.6 ± 0.3 0.1
GGT (xULN)a 2.2 ± 2.6 2.1 ± 1.8 0.6
Bilirubin (mg/dL)a 1 ± 1.7 0.9 ± 0.5 0.2
Prothrombin activitya 88 ± 17 91 ± 12 0.16
Albumin (g/dL)a 4 ± 0.4 4.2 ± 0.4 0.01
Platelets (n/mm3)a 187,200 ± 60,427 180,977 ± 67,587 0.5
Fibrosis, 0-2/3-4* 81/19 65/35 0.03
Activity grade, 0-1/2-3* 64/36 53/47 0.1
Hepatic steatosis, yes/no* 49/51 75/25 0.001
BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyltransferase; ULN: upper limit 
of normal. *Numbers are expressed as percentages. Data analysis was performed using the chi-square test, Student’s t-test and Mann-Whitney 
test. a Mean ± SD. Histological analysis was performed according to the METAVIR system.
Another ﬁ nding of the present study was the association 
between HCV-3 and more advanced stages of ﬁ brosis. Several 
risk factors have been associated with the histological progression 
of chronic hepatitis C, such as the duration of infection, age at 
infection, body weight, alcohol consumption, and double infection 
with HBV or HIV. However, the contribution of the HCV genotype 
to the progression of liver ﬁ brosis is unclear. Bochud et al.34 
estimated the progression rate of ﬁ brosis (METAVIR score/time 
of infection in years) in 1,189 patients and found a signiﬁ cant 
association between genotype 3 and advanced liver ﬁ brosis. 
Genotype 3 was identiﬁ ed as an independent risk factor for 
ﬁ brosis progression (OR=1.89, 95%CI: 1.37-2.61, p<0.001), as 
individuals with this genotype presented a higher progression rate 
compared to individuals with the other genotypes. In a systematic 
review of the literature conducted by Prosbt et al.35, genotype 3 
was associated with more rapid progression of liver ﬁ brosis.
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Possible explanations for the more advanced ﬁ brosis in 
patients with genotype 3 include the presence of other factors 
associated with ﬁ brosis progression, such as excessive alcohol 
consumption, greater pathogenicity of this genotype in terms 
of its ability to induce liver ﬁ brosis, and the association with 
hepatic steatosis. Because alcohol abuse was excluded from the 
present study, this factor is not likely to explain the ﬁ nding of 
more advanced ﬁ brosis in this group of patients. It is therefore 
likely that characteristics of the genotype 3 itself, or the 
association of this genotype with steatosis are responsible for 
this ﬁ nding. In this respect, studies have suggested that hepatic 
steatosis is associated with ﬁ brosis progression in patients 
infected with genotype 3. Westin et al.36 studied 98 patients with 
genotype 3 (n=25) and non-genotype 3 (n=64) HCV who were 
submitted to two liver biopsies and observed that the prevalence 
and degree of steatosis were strongly associated with genotype 
3, irrespective of gender, age, BMI, and alcohol consumption. 
Faster ﬁ brosis progression was more prevalent in patients with 
hepatic steatosis, an effect that was observed mainly in patients 
infected with genotype 3. 
It can be concluded that differences exist between HVC-2 
and HVC-3. Patients infected with HCV-3 were younger and had 
less frequent arterial hypertension; additionally, the prevalence 
of advanced liver ﬁ brosis and hepatic steatosis was higher in 
these patients when compared to patients infected with HCV-
2. These differences suggest that genotypes 2 and 3 should be 
analyzed separately, as they are genotypes with different clinical 
and histopathological characteristics.
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